Bioprocessing advances are reshaping biologics manufacturing with intensified fed-batch processes delivering 5-10 fold productivity increases while simplifying operations, as presented by Sanofi's senior scientist Yuxin Liu. Cytiva highlighted chromatography optimization for evolving monoclonal antibody formats to balance efficiency, sustainability, and cost. Meanwhile, GSK announced a $30 billion US investment plan over five years for manufacturing and R&D infrastructure. These efforts reflect the biopharma industry's drive toward efficiency, scalability, and reshoring amid global supply challenges and drug pipeline diversification.